The potential of antidiabetic thiazolidinediones for anticancer therapy

Area of Science:

• Pharmacology
• Oncology
• Endocrinology

Background:

• Thiazolidinediones (TZDs) are synthetic compounds primarily used for treating insulin-resistant Type 2 diabetes mellitus.
• TZDs are known activators of peroxisome proliferator-activated receptor-gamma (PPAR-gamma), mediating their antidiabetic effects.
• Emerging evidence suggests PPAR-gamma-independent actions and broader biological effects, including cell growth and programmed cell death.

Purpose of the Study:

• To review the molecular mechanisms underlying the antineoplastic actions of TZDs.
• To assess the relevance of these findings in human pathology and cancer therapy.
• To consolidate understanding of TZDs beyond their metabolic roles.

Main Methods:

• Literature review of experimental studies on TZDs' effects on cancer.
• Analysis of molecular mechanisms of TZD-induced antineoplastic activity.
• Evaluation of in vitro, animal model, and clinical trial data.

Main Results:

• TZDs exhibit anticancer effects through various molecular pathways, some independent of PPAR-gamma.
• In vitro studies show promising anticancer potential, but animal models and pilot trials yield controversial results.
• TZDs influence cell growth, differentiation, motility, and apoptosis, relevant to cancer biology.

Conclusions:

• TZDs possess multifaceted biological activities with potential anticancer applications.
• Further research is needed to reconcile conflicting results and optimize TZD use in oncology.
• Understanding TZDs' molecular mechanisms is crucial for their therapeutic relevance in human cancer.